/Gilead%20Sciences%2C%20Inc_%20pills-by%20%20Marc%20Bruxelle%20via%20Shutterstock.jpg)
Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a global biopharmaceutical leader committed to discovering, developing, and delivering transformative therapies for life-threatening diseases. The company, currently valued at a market cap of $134.7 billion, has established a strong presence across several critical therapeutic areas, including HIV, viral hepatitis, oncology, and inflammatory diseases.
Gilead has been a pioneer in antiviral research, particularly in the treatment and prevention of HIV/AIDS, where its therapies have significantly improved patient outcomes and quality of life. The company is set to release its fiscal Q2 earnings results on Thursday, Aug. 14. Ahead of the event, analysts expect GILD to report a profit of $1.96 per share, down 2.5% from $2.01 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in three of the past four quarters, while missing in the recent quarter.
